Stem Cell Therapeutics Corp. Announces the Publication of Key Animal Data to Support Efficacy of Its Stroke Regimen NTx(R)-265 i

  Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or "the Company") announces the acceptance and publication of a paper describing the effectiveness of the NTx®-265 stroke treatment regimen when administered 24 hours after an ischemic stroke in rats.

For the first time, this therapeutic strategy was shown to improve behavioral outcome and reduced lesion volume with a time window of 24 hours after the onset of stroke. These fundamental results provided the evidence necessary to advance NTx®-265 into the initial BETAS human stroke studies in acute ischemic stroke.

Dr. Allen Davidoff, VP of Product Development commented as follows:

"These exciting preclinical data formed the efficacy basis for our move to the clinic, and it's encouraging to see publication of these data in a quality, peer-reviewed journal."

The paper which is titled "A Novel Neurotrophic Therapeutic Strategy for Experimental Stroke" will appear in the scientific journal Brain Research (2009) and is currently available online.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President and CEO 403-245-5495 ext.224 [e-mail] Stem Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations 403-245-5495 ext. 221 [e-mail] www.stemcellthera.com